Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianqu Qingshen Xiaoke granules
- Development stage
- Preclinical
- Lead developer
- Tasly Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lianqu Qingshen Xiaoke granules (JX99) is an investigational Traditional Chinese Medicine (TCM) formulation developed for the treatment of metabolic syndrome. It is a multi-herb product comprising extracts from Coptidis Rhizoma, Aurantii Fructus Immaturus, Pinelliae Rhizoma, red yeast rice, Trichosanthis Fructus, and Cinnamomi Cortex. The formulation is designed to improve glucose and lipid metabolism and ameliorate insulin resistance. Its mechanism of action involves the activation of the AMP-activated protein kinase (AMPK) signaling pathway and the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the latter likely due to the presence of natural monacolins in the red yeast rice component. It is currently being evaluated in clinical studies for its efficacy in managing metabolic syndrome.
- Other names
- Lianqu Qingshen Xiaoke
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on Lianqu Qingshen Xiaoke granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lianqu Qingshen Xiaoke granules.